vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and Maison Solutions Inc. (MSS). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $27.6M, roughly 1.4× Maison Solutions Inc.). Maison Solutions Inc. runs the higher net margin — -18.0% vs -161.8%, a 143.8% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -10.9%).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
Maison Solutions Inc.MSSEarnings & Financial Report
Maison Solutions Inc. is a specialty home goods retail company that provides a diverse portfolio of stylish, affordably priced furniture, home decor items, and daily household products. Its primary market is the Guangdong-Hong Kong-Macao Greater Bay Area in China, serving mass consumers through both offline physical stores and online e-commerce channels.
IBRX vs MSS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $27.6M |
| Net Profit | $-61.9M | $-5.0M |
| Gross Margin | 99.0% | 23.4% |
| Operating Margin | -169.0% | -4.9% |
| Net Margin | -161.8% | -18.0% |
| Revenue YoY | 407.0% | -10.9% |
| Net Profit YoY | -4.7% | -1840.5% |
| EPS (diluted) | $-0.06 | $-0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $27.6M | ||
| Q3 25 | $32.1M | $27.2M | ||
| Q2 25 | $26.4M | $34.4M | ||
| Q1 25 | $16.5M | $32.3M | ||
| Q4 24 | $7.6M | $29.4M | ||
| Q3 24 | $6.1M | $28.2M | ||
| Q2 24 | — | $16.9M | ||
| Q1 24 | — | $13.6M |
| Q4 25 | $-61.9M | $-5.0M | ||
| Q3 25 | $-67.3M | $-1.5M | ||
| Q2 25 | $-92.6M | $-287.4K | ||
| Q1 25 | $-129.6M | $1.0M | ||
| Q4 24 | $-59.2M | $-256.0K | ||
| Q3 24 | $-85.7M | $700.9K | ||
| Q2 24 | — | $-2.8M | ||
| Q1 24 | — | $-549.0K |
| Q4 25 | 99.0% | 23.4% | ||
| Q3 25 | 99.4% | 24.1% | ||
| Q2 25 | 99.5% | 9.5% | ||
| Q1 25 | 99.6% | 21.8% | ||
| Q4 24 | — | 26.9% | ||
| Q3 24 | — | 28.9% | ||
| Q2 24 | — | 13.0% | ||
| Q1 24 | — | 23.4% |
| Q4 25 | -169.0% | -4.9% | ||
| Q3 25 | -173.5% | 0.7% | ||
| Q2 25 | -269.8% | -15.9% | ||
| Q1 25 | -390.1% | 3.7% | ||
| Q4 24 | -919.0% | 3.2% | ||
| Q3 24 | -1314.3% | 7.3% | ||
| Q2 24 | — | -14.4% | ||
| Q1 24 | — | -2.3% |
| Q4 25 | -161.8% | -18.0% | ||
| Q3 25 | -209.8% | -5.7% | ||
| Q2 25 | -350.3% | -0.8% | ||
| Q1 25 | -784.9% | 3.1% | ||
| Q4 24 | -783.4% | -0.9% | ||
| Q3 24 | -1404.0% | 2.5% | ||
| Q2 24 | — | -16.4% | ||
| Q1 24 | — | -4.0% |
| Q4 25 | $-0.06 | $-0.23 | ||
| Q3 25 | $-0.07 | $-0.08 | ||
| Q2 25 | $-0.10 | $-0.02 | ||
| Q1 25 | $-0.15 | $0.06 | ||
| Q4 24 | $-0.08 | $-0.01 | ||
| Q3 24 | $-0.14 | $0.04 | ||
| Q2 24 | — | $-0.16 | ||
| Q1 24 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | — |
| Total DebtLower is stronger | — | $2.6M |
| Stockholders' EquityBook value | $-500.5M | $11.6M |
| Total Assets | $501.9M | $75.4M |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | — | ||
| Q3 25 | $257.8M | $1.1M | ||
| Q2 25 | $153.7M | $775.4K | ||
| Q1 25 | $61.6M | $445.4K | ||
| Q4 24 | $149.8M | $355.7K | ||
| Q3 24 | $130.4M | $588.9K | ||
| Q2 24 | — | $2.1M | ||
| Q1 24 | — | $9.4M |
| Q4 25 | — | $2.6M | ||
| Q3 25 | — | $2.6M | ||
| Q2 25 | — | $2.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $2.5M | ||
| Q2 24 | — | $2.6M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | $-500.5M | $11.6M | ||
| Q3 25 | $-524.3M | $10.1M | ||
| Q2 25 | $-570.7M | $11.7M | ||
| Q1 25 | $-591.4M | $12.0M | ||
| Q4 24 | $-489.1M | $10.9M | ||
| Q3 24 | $-745.1M | $11.2M | ||
| Q2 24 | — | $10.5M | ||
| Q1 24 | — | $13.3M |
| Q4 25 | $501.9M | $75.4M | ||
| Q3 25 | $519.0M | $73.3M | ||
| Q2 25 | $402.1M | $77.4M | ||
| Q1 25 | $303.8M | $82.7M | ||
| Q4 24 | $382.9M | $82.7M | ||
| Q3 24 | $364.6M | $82.1M | ||
| Q2 24 | — | $82.4M | ||
| Q1 24 | — | $44.2M |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.22× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $-1.7M |
| Free Cash FlowOCF − Capex | $-71.3M | — |
| FCF MarginFCF / Revenue | -186.2% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $-1.7M | ||
| Q3 25 | $-68.9M | $1.1M | ||
| Q2 25 | $-79.7M | $-1.6M | ||
| Q1 25 | $-85.9M | $1.7M | ||
| Q4 24 | $-85.1M | $1.1M | ||
| Q3 24 | $-98.8M | $3.6M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-1.4M |
| Q4 25 | $-71.3M | — | ||
| Q3 25 | $-69.6M | — | ||
| Q2 25 | $-80.8M | — | ||
| Q1 25 | $-87.0M | — | ||
| Q4 24 | $-87.3M | — | ||
| Q3 24 | $-101.6M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -186.2% | — | ||
| Q3 25 | -217.2% | — | ||
| Q2 25 | -305.9% | — | ||
| Q1 25 | -526.9% | — | ||
| Q4 24 | -1155.4% | — | ||
| Q3 24 | -1663.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 28.0% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.66× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 5.12× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IBRX
Segment breakdown not available.
MSS
| Perishables | $14.4M | 52% |
| Nonperishables | $13.2M | 48% |
